文献速递泌尿男性生殖肿瘤

健康专业人员随访研究中酒精摄入与致死性前列腺癌风险

Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
PubMed 文献 · J Clin Oncol · 2019-04-26

该前瞻性队列研究利用健康专业人员随访研究(1986至2012年),在47,568名无癌男性中分析酒精摄入与致死性前列腺癌诊断的关联,并在5,182名非转移性前列腺癌患者中分析饮酒与转移或死亡的关联。结果显示饮酒者致死性前列腺癌风险略低(任何饮酒 vs 不饮酒:HR 0.84,95%CI 0.71-0.99),前列腺癌诊断后中度红酒摄入与致死性进展风险降低相关(任何饮酒 vs 不饮酒:HR 0.50,95%CI 0.29-0.86)。作者认为这些关联值得进一步研究,但中度饮酒对前列腺癌患者是安全的。

要点

  • 无癌男性中,任何饮酒 vs 不饮酒的致死性前列腺癌HR为0.84(95%CI 0.71-0.99),无剂量反应关系。
  • 前列腺癌患者中,任何饮酒 vs 不饮酒与致死性进展无关(HR 0.99,95%CI 0.57-1.72)。
  • 前列腺癌诊断后中度红酒摄入 vs 不饮酒与致死性进展风险降低相关(HR 0.50,95%CI 0.29-0.86;P趋势=.05)。

核心结论

  • 无癌男性中饮酒者致死性前列腺癌风险略低于不饮酒者。
  • 前列腺癌患者中红酒摄入与致死性进展风险降低相关。
  • 作者认为这些关联值得进一步研究,但中度饮酒对前列腺癌患者是安全的。

研究设计与样本

  • 前瞻性队列研究,使用健康专业人员随访研究(1986至2012年)数据。
  • 无癌男性分析纳入47,568名无癌男性。
  • 前列腺癌患者分析限于随访期间诊断的非转移性前列腺癌患者5,182名。
  • 采用多因素Cox比例风险回归估计HR和95%CI。

主要发现

  • 无癌男性中,任何饮酒 vs 不饮酒的致死性前列腺癌HR为0.84(95%CI 0.71-0.99),无剂量反应关系。
  • 前列腺癌患者中,任何饮酒 vs 不饮酒与致死性前列腺癌进展无关(HR 0.99,95%CI 0.57-1.72)。
  • 前列腺癌患者中,中度红酒摄入 vs 不饮酒与致死性前列腺癌风险降低相关(HR 0.50,95%CI 0.29-0.86;P趋势=.05)。
  • 前列腺癌诊断后每日总酒精15至30克 vs 不饮酒与死亡风险降低相关(HR 0.71,95%CI 0.50-1.00)。
  • 前列腺癌诊断后红酒摄入 vs 不饮酒与死亡风险降低相关(HR 0.74,95%CI 0.57-0.97;P趋势=.007)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为这些观察到的关联值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It is unknown whether alcohol intake is associated with the risk of lethal (metastatic or fatal) prostate cancer. We examine (1) whether alcohol intake among men at risk of prostate cancer is associated with diagnosis of lethal prostate cancer and (2) whether intake among men with nonmetastatic prostate cancer is associated with metastasis or death. METHODS: This prospective cohort study uses the Health Professionals Follow-Up Study (1986 to 2012). Our analysis of alcohol intake among men at risk of prostate cancer included 47,568 cancer-free men. Our analysis of alcohol intake among men with prostate cancer was restricted to 5,182 men diagnosed with nonmetastatic prostate cancer during follow-up. We examine the association of total alcohol, red and white wine, beer, and liquor with lethal prostate cancer and death. Multivariate Cox proportional hazards regression estimated hazard ratios (HRs) and 95% CIs. RESULTS: Alcohol drinkers had a lower risk of lethal prostate cancer (any v none: HR, 0.84 [95% CI, 0.71 to 0.99]) without a dose-response relationship. Total alcohol intake among patients with prostate cancer was not associated with progression to lethal prostate cancer (any v none: HR, 0.99 [95% CI, 0.57 to 1.72]), whereas moderate red wine intake was associated with a lower risk (any v none: HR, 0.50 [95% CI, 0.29 to 0.86]; P trend = .05). Compared with none, 15 to 30 g/d of total alcohol after prostate cancer diagnosis was associated with a lower risk of death (HR, 0.71 [95% CI, 0.50 to 1.00]), as was red wine (any v none: HR, 0.74 [95% CI, 0.57 to 0.97]; P trend = .007). CONCLUSION: Cancer-free men who consumed alcohol had a slightly lower risk of lethal prostate cancer compared with abstainers. Among men with prostate cancer, red wine was associated with a lower risk of progression to lethal disease. These observed associations merit additional study but provide assurance that moderate alcohol consumption is safe for patients with prostate cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Downer MK, Kenfield SA, Stampfer MJ, et al. Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. J Clin Oncol. 2019. PMID: 31026211. doi:10.1200/JCO.18.02462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。